phrykt

TScan Therapeutics, Inc. (TCRX): who owns it and who trades it

As of Nov 16, 2026, TCRX insiders reported 3 purchases worth $146K in the last 12 months. The largest buyer was Lynx1 Capital Management LP (10% owner), with $146K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling TScan Therapeutics

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Insiders mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TCRX

59 funds and institutions reported TCRX shares worth $35.6M at the end of Q2 2026. The largest holder is Lynx1 Capital Management LP with $7.9M.

10 largest owners, by value

Lynx1 Capital Management LP$7.9M
Bvf Inc$5.5M
Baker Bros. Advisors LP$2.7M
Vanguard Capital Management LLC$2.1M
Two Sigma Investments, LP$1.9M
Renaissance Technologies LLC$1.3M
Acadian Asset Management LLC$1.3M
Deer Management Co. LLC$1.2M
Millennium Management LLC$1.1M
Jacobs Levy Equity Management, Inc$1M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Lynx1 Capital Management LP8.02M–$7.9MNo change
Bvf Inc5.56M–$5.5MNo change
Baker Bros. Advisors LP2.78M–$2.7MNo change
Vanguard Capital Management LLC2.16M–$2.1M+0%
Two Sigma Investments, LP1.95M–$1.9M+61%
Renaissance Technologies LLC1.33M–$1.3M-3%
Acadian Asset Management LLC1.31M–$1.3M+546%
Deer Management Co. LLC1.25M–$1.2MNo change
Millennium Management LLC1.16M–$1.1M-20%
Jacobs Levy Equity Management, Inc1.05M–$1M+30%
Citadel Advisors LLC1.01M–$989K+217%
BlackRock, Inc.994,654–$975K-46%
Kalehua Capital Management LLC909,752–$892KNew
Boothbay Fund Management, LLC772,241–$757KNew
Marshall Wace, LLP687,364–$674K+190%
DC Funds, LP630,000–$617KNo change
Geode Capital Management, LLC584,811–$573K-5%
D. E. Shaw & Co., Inc.548,402–$537K+72%
Gsa Capital Partners LLP548,087–$537K+45%
Vanguard Fiduciary Trust Co363,954–$357K+19%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TCRX insiders reported $146K of open-market purchases and $0 of sales.

Purchases, 12 months
$146K
3 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Dec 23, 2025
Filed Dec 23, 2025

Purchases and sales by month

$146K$146KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Dec 23, 2025Lynx1 Capital Management LP +110% ownerPurchase6,232$0.90$5.6KForm 4
Dec 22, 2025Lynx1 Capital Management LP +110% ownerPurchase75,500$0.90$68KForm 4
Dec 19, 2025Lynx1 Capital Management LP +110% ownerPurchase80,069$0.90$72.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Lynx1 Capital Management LP10% owner$146K–Dec 23, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TCRX short interest

2.02M TCRX shares are sold short. Over the last 12 reports the number of shares short went up 131%.

As of Oct 30, 2026, 2.02M TCRX shares were sold short, down 11.3% from the report before. At the average daily volume of 432,876 shares, buying them all back would take about 4.7 trading days (days to cover).

Shares short

2.02MMay 15Oct 302.75M

Days to cover

4.7May 15Oct 307.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.02M–-11%432,8764.7
Oct 15, 20262.28M–-8%669,3593.4
Sep 30, 20262.49M–+9%764,4303.2
Sep 15, 20262.28M–+30%1.97M1.2
Aug 31, 20261.75M–+9%250,9977.0
Aug 14, 20261.60M–+3%377,8944.2
Jul 31, 20261.56M–+13%560,6852.8
Jul 15, 20261.38M–+95%1.16M1.2
Jun 30, 2026708,200–-7%782,9251.0
Jun 15, 2026762,526–-18%392,3901.9
May 29, 2026934,310–+7%457,5922.0
May 15, 2026876,559–+1%840,6061.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

TScan Therapeutics company events

TScan Therapeutics filed 13 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership, listing). The latest was on Oct 16, 2026.

  1. Oct 16, 2026LeadershipEach of Garry Nicholson and Gabriela Gruia, M.D., resigned from the Board of Directors of TScan Therapeutics, Inc. and each committee thereof, in each case effective as of October 13, 2026. Filing
  2. Sep 30, 2026LeadershipAs previously disclosed in the Company’s Current Report on Form 8-K filed September 2, 2026, in connection with a strategic reorganization of the Company, it was agreed that Jason A. Amello would cease to serve as the Company’s Chief Financial Officer and Chrystal Louis, M.D., MPH, would cease to… Filing
  3. Sep 11, 2026LeadershipThe Compensation Committee of the Board of Directors of TScan Therapeutics, Inc. approved a retention program designed to retain the employees required to support the Company, including a key employee retention program that provides for cash awards and the potential future grant of equity-based… Filing
  4. Sep 2, 2026ListingThe Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that the Company’s voting common stock, par value $0.0001 per share failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Global Market… Filing
  5. Aug 18, 2026AgreementEnded an important agreement. Filing
  6. Aug 12, 2026ResultsReleased financial results. Filing
  7. Jun 22, 2026AnnouncementThe Company provided an update on its heme malignancies clinical program, including initial data from Cohort C of the ongoing ALLOHA ™ Phase 1 study evaluating TSC-101, generated with the commercial-ready manufacturing process, in patients with heme malignancies undergoing allogeneic hematopoietic… Filing
  8. May 22, 2026VoteReported shareholder vote results. Filing
  9. May 6, 2026ResultsReleased financial results. Filing
  10. Apr 2, 2026LeadershipLeiden Dworak notified TScan Therapeutics, Inc. of his decision to resign as Vice President of Finance of the Company and principal accounting officer effective April 10, 2026. Filing
  11. Mar 4, 2026ResultsReleased financial results. Filing
  12. Jan 12, 2026AnnouncementShared information with investors. Filing
  13. Nov 26, 2025LeadershipThe Board of Directors of TScan Therapeutics, Inc., upon the recommendation of the Compensation Committee, approved a retention program designed to retain the employees required to support the Company, including a key employee retention program that provides for cash awards and the potential future… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

TScan Therapeutics financials

Famous investors that hold TCRX

2 of the 50 well-known investors we track reported holding TCRX in their latest 13F filing. The largest position is Jim Simons's, worth $380K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.21M$380K0.0%-9%
Ken Griffin · Citadel AdvisorsQ3 202651,756$16.3K0.0%-95%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about TScan Therapeutics, Inc. (TCRX) stock

Who owns the most TCRX stock?

The largest reported owner of TScan Therapeutics, Inc. (TCRX) is Lynx1 Capital Management LP. In total, 59 funds and institutions reported holding TCRX at the end of Q2 2026. See the largest owners.

Are TCRX insiders buying or selling?

In the last 12 months, TCRX insiders reported 3 open-market purchases worth $146K and no sales. The latest trade was on Dec 23, 2025. See every trade.

What is the short interest in TCRX?

As of Oct 30, 2026, 2.02M TCRX shares were sold short, down 11.3% from the report before. At the average daily volume of 432,876 shares, buying them all back would take about 4.7 trading days (days to cover). See the history.

Which famous investors hold TCRX?

2 of the 50 well-known investors we track reported TCRX in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $380K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.